Atea Pharmaceuticals, Inc. Common Stock (AVIR) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$4.57
- 52-Week Range
- $2.46 – $6.45
- YTD
- +31.32%
- IV Rank (30D)
- 61.36
- Straddle Price
- $1.88
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.4B
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.24% | 6 |
| Feb | -3.47% | 6 |
| Mar | +0.99% | 6 |
| Apr | -13.09% | 6 |
| May | +7.00% | 6 |
| Jun | -1.70% | 5 |
| Jul | +9.09% | 5 |
| Aug | +1.40% | 5 |
| Sep | -9.70% | 5 |
| Oct | -10.89% | 5 |
| Nov | -11.21% | 5 |
| Dec | +5.27% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.51
SMA 50: $5.64
SMA 200: $4.01
Current: $4.57
EMA 12: $5.38
EMA 26: $5.48
MACD: -0.0932 | Signal: -0.0774
BEARISH
ADX (14): 18.21
RANGE
+DI: 9.67
−DI: 32.90
Momentum Oscillators
RSI (14): 28.36
OVERSOLD
Stoch %K: 25.69
Stoch %D: 32.67
Williams %R: -95.82
Volume & Volatility
BB Upper: $5.98
BB Lower: $5.03
OVERSOLD
OBV: 13,233,110
Vol SMA 20: 302,460
Vol ROC: 155.84%
ATR: $0.29
True Range: $0.99
HV 20: 71.9%
HV 30: 63.5%
HV 60: 59.2%
Data Summary
Data Points: 500
Last Updated: 2026-05-13T21:15:18.147000
Date Range: 2024-05-15T00:00:00 – 2026-05-13T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Recent positive news headlines related to preclinical results, new data supporting hepatitis E virus treatment potential
- Oversold technical conditions with RSI at 28.36 and Bollinger Bands oversold signal
- Moderate volatility and correlation with market
Primary risks:
- Regulatory challenges or setbacks in the development of AT-587 for hepatitis E virus treatment
- Competition from existing treatments or emerging players in the hepatitis C virus market
Investment thesis: AVIR presents a moderate-risk opportunity with potential for upside, driven by positive news sentiment and technical oversold conditions.
Recent news sentiment impact:
- Positive news headlines have contributed to the stock's recent move, with 3 out of 6 recent news articles having a positive sentiment (50%)
Technical Analysis
Trend Direction: Short-term bearish trend (1-4 weeks), Medium-term range-bound (1-3 months), Long-term bullishly inclined (3-12 months)
Support/Resistance Levels:
- Lower Bollinger Band: $5.03
- Middle Bollinger Band: $5.51
- Upper Bollinger Band: $5.98
Momentum Signals:
- RSI interpretation: Oversold at 28.36
- MACD signal: Bearish
- Bollinger Bands position: Oversold with a strong buy signal
News & Sentiment Analysis
Recent Headlines Summary: Recent news articles highlight positive developments in the treatment of hepatitis E virus and C virus, reinforcing AVIR's potential as a leader in this space.
Sentiment Assessment: Positive sentiment dominates recent news headlines (50%), contributing to the stock's upward movement.
Catalyst Identification: Upcoming earnings reports and regulatory updates on AT-587 could drive market moves.
Market Narrative: Technical signals align with positive news sentiment, indicating potential for further upside.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to market (beta 0.88)
Volatility Regime: Current volatility is moderate, with historical volatility ranging from 59.2% to 71.9%
Options Market Signals:
- IV rank: Medium (61.4%)
- Put/call ratio: Bullish sentiment
- Unusual activity: None noted
Market Context & Positioning
Sector Performance: AVIR's sector, Biotechnology, has shown moderate growth.
Institutional Activity: Institutional interest remains moderate, with no significant buying or selling pressure observed.
Correlation Analysis: Correlation with market is moderate (0.22).
Relative Valuation: AVIR's relative valuation is neutral within its trading range.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $5.03
- Middle Bollinger Band: $5.51
- Upper Bollinger Band: $5.98
Breakout/Breakdown Levels: None noted, but significant technical signals can be expected near the middle and upper Bollinger Bands.
Time-Sensitive Catalysts: Upcoming earnings reports and regulatory updates on AT-587 could drive market moves.
Risk Management: Monitor price action and adjust position sizing accordingly. Consider stop-loss levels at key technical support/resistance points.
Please note that this analysis is based solely on the provided data and does not constitute investment advice. It is essential to consider additional factors, such as a company's financials, management team, industry trends, and market conditions, before making any investment decisions.
Generated 2026-05-13 17:36 UTC
News
Options Activity
- IV Rank (30D)
- 61.36
- IV Rank (7D)
- 100
- Avg IV
- 243.4%
- Straddle (30D)
- $1.88
- Straddle (7D)
- $1.12
- P/C Volume
- 0.00
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.88
- Correlation (SPY)
- 22.0%
- R²
- 0.05
- Ann. Volatility
- 48.3%
- SPY Volatility
- 12.1%
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 82,363,523 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$10.00K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $9.64K | 96.43% | 2025-12-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $357 | 3.57% | 2025-12-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.6 |
| EV/EBITDA | -1.9 |
| ROE | -57.5% |